Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients

2018 ◽  
Vol 39 (8) ◽  
pp. 1423-1430 ◽  
Author(s):  
Bonaventura Casanova ◽  
Laura Lacruz ◽  
María Luisa Villar ◽  
José Andrés Domínguez ◽  
María Carcelén Gadea ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Multiple Sclerosis Patients

scholarly journals Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort

2012 ◽  
Vol 70 (10) ◽  
pp. 774-779 ◽  
Author(s):  
Valéria Coelho Santa Rita Pereira ◽  
Fabíola Rachid Malfetano ◽  
Isabella D'Andrea Meira ◽  
Letícia Fêzer de Souza ◽  
Assuncion Martinez Liem ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Treatment Response ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Response To Treatment ◽  
Clinical Criteria ◽  
Significant Difference ◽  
One Year ◽  
Multiple Sclerosis Patients

INTRODUCTION: Many patients with multiple sclerosis (MS) are currently receiving treatment with interferon beta (IFNb) and glatiramer acetate (GA). Identifying nonresponders patients is important to define therapy strategies. Several criteria for treatment response to IFNb and GA have been proposed. OBJECTIVE: It was to investigate the response to treatment with IFNb-1a, IFNb-1b and GA among relapsing-remitting multiple sclerosis (RRMS) patients. METHODS: We analyzed treatment response to IFNb and GA in ninety-one RRMS patients followed for at least one year. Clinical response was established by clinical criteria based on relapses, disability progression or both. RESULTS: We observed a proportion of nonresponders, ranging from 3.3 to 42.9%, depending on the stringency of the criteria used. CONCLUSIONS: Our sample of Brazilian patients with MS has similarities when compared to other studies and there was no statistically significant difference regarding age, gender, ethnicity or disease duration between responders and nonresponders.

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate

2018 ◽  
Vol 394 ◽  
pp. 127-131 ◽  
Author(s):  
Brian C. Healy ◽  
Bonnie I. Glanz ◽  
Jonathan D. Zurawski ◽  
Maria Mazzola ◽  
Tanuja Chitnis ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Long Term Follow Up ◽  
Multiple Sclerosis Patients

Patterns of Th1/Th2 Cytokines Predict Clinical Response in Multiple Sclerosis Patients Treated with Glatiramer Acetate

2011 ◽  
Vol 65 (3) ◽  
pp. 164-169 ◽  
Author(s):  
Hayrettin Tumani ◽  
Jan Kassubek ◽  
Mohammed Hijazi ◽  
Vera Lehmensiek ◽  
Alexander Unrath ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Clinical Response ◽  
Glatiramer Acetate ◽  
Th2 Cytokines ◽  
Multiple Sclerosis Patients

Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study

2014 ◽  
Vol 20 (9) ◽  
pp. 1265-1268 ◽  
Author(s):  
Giovanni Frisullo ◽  
Massimiliano Calabrese ◽  
Carla Tortorella ◽  
Damiano Paolicelli ◽  
Paolo Ragonese ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Glatiramer Acetate ◽  
Interferon Beta ◽  
Thyroid Autoimmunity ◽  
Term Treatment ◽  
First Year ◽  
Close Monitoring ◽  
Long Term Treatment ◽  
Multiple Sclerosis Patients

Few long-term follow-up data are available on thyroid dysfunction (TD) in multiple sclerosis (MS) patients treated with glatiramer acetate (GA) or with interferon-beta (IFNb). In a cohort of 787 relapsing–remitting MS (RRMS) patients whom were followed up for 8 years, we observed an increased prevalence of TD and thyroid autoimmunity (TA) within the first year of IFNb treatment, regardless of the dose or frequency of administration, while no change was observed with GA treatment. The increased prevalence of TD and TA within the first year of IFNb treatment suggested the need for close monitoring of thyroid function and autoimmunity, though only during the first year of IFNb treatment.

Sign in / Sign up

Export Citation Format

Share Document